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Abstract
Background: There are no standard criteria for when to discontinue intravenous antimicrobial
therapy (IVAMT) in children with febrile neutropenia (FN), but it is now common to discontinue
IVAMT and discharge patients with an absolute neutrophil count (ANC) ≤  500 /mm3. The purpose
of this study was to evaluate the outcome of a large cohort of children with FN who had IVAMT
discontinued with an ANC ≤  500 /mm3
Methods: A retrospective chart review was completed of patients in the Northern Alberta
Children's Cancer Program with FN and no apparent clinical source of fever from June 1, 1997 to
July 1, 2002.
Results: Out of a total of 275 patients, 127 (46%) had at least one episode of FN, with FN
occurring in patients with sarcomas more commonly than in those with leukemia/ lymphoma and
least in those with other solid tumors. In 59 of 276 episodes of FN (21%) patients had a
microbiologically defined infection at admission. Of the 217 remaining episodes, 112 of 199 patients
(56%) with known neutrophil counts had IVAMT discontinued before their absolute neutrophil
count (ANC) reached 500 /mm3 at the discretion of the clinician. Fever recurred in only two of
these patients after discharge, and there were no bacterial infections diagnosed after parenteral
antibiotics were discontinued.
Conclusion: Even without use of standard criteria for early discharge, clinicians appear to be
skilled at selecting children with FN who can safely have IVAMT discontinued with an ANC ≤  500
/mm3.
Background
Febrile neutropenia (FN) is a common problem in pediat-
ric oncology patients. The majority of patients with FN do
not have a microbiologically defined infection (MDI), but
those who do are at risk for overwhelming sepsis. It is
therefore standard practice to start empiric intravenous
(IV) antibiotics if the absolute neutrophil count (ANC) is
below 500–1000/mm3 [1]. However, there are no defini-
tive guidelines on the endpoints for stopping antibiotics if
a bacterial source is not found for the fever, nor is it clear
if the antibiotics need to be given by IV for the entire
course. Physicians must balance the potential risk of inad-
equate antibiotic therapy with the potential risk of antibi-
otic resistance from overuse of antibiotics, while taking
into consideration the emotional, social, and financial
costs to hospitalized children and their families.
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Management of FN in the Northern Alberta Children's
Cancer Program (NACCP) has traditionally consisted of
broad spectrum IVAMT (usually tobramycin and pipera-
cillin) until the patient is afebrile, blood cultures are neg-
ative at ≥  48 hours incubation, and the ANC is > 500/
mm3. However, in recent years, there has been a trend
towards discontinuing IVAMT in children who do not
have an ANC > 500/mm3. Clinicians have used their clin-
ical judgment rather than standard criteria in deciding
when to discontinue IVAMT. The objective of this study
was to document the clinical course and outcome of FN in
the face of this changing management.
Methods
Patients
Children ≤  17 years of age receiving therapy for a primary
or recurrent malignancy through the NACCP from June 1,
1997 to July 1, 2002 were enrolled in this study. Inpatient
charts were reviewed for these patients at the Stollery Chil-
dren's Hospital in Edmonton to document the details of
all FN episodes. Outpatient charts were also reviewed to
determine if the fever recurred after hospital discharge.
Fever was defined as a temperature ≥  38.0 degrees Celsius
(°C) measured either at home or in hospital. Neutropenia
was defined as an ANC ≤  500/mm3. Children with leuke-
mia who were not yet in remission were excluded from
this study as they usually have concomitant complications
that prolong hospitalization beyond resolution of the FN.
Data collection
For each episode of FN, data was compiled from the time
of diagnosis of FN until discharge from hospital or death.
If cultures done during the first 48 hours of the admission
were positive for an organism that would account for the
fever, no further data was collected. Fever was not attrib-
uted to beta-hemolytic streptococci isolated from a throat
swab, as the carrier state is common. Fever was not attrib-
uted to toxin producing Clostridium difficile in stool, as
symptomatic or asymptomatic carriage is common in
pediatric oncology patients, yet fever is expected only with
severe disease. Organisms isolated from blood cultures
were considered contaminants if common skin organisms
were isolated from a single blood culture.
For all admissions for FN where an infectious etiology was
not identified from cultures done within 48 hours of
admission, data was collected on the choice and duration
of IVAMT (including outpatient antibiotics), use of oral
antibiotics for empiric treatment of FN, use of systemic
anti-fungal agents, microbiologic laboratory results, abso-
lute phagocytic count (APC), ANC, absolute monocyte
count (AMC), length of stay in hospital attributable to FN,
duration of fever and recurrence of fever during or after
the admission. A recurrent fever was defined as a new
fever that occurred after the patient had been afebrile for
≥  24 hours, and before they had an ANC > 500/mm3.
Statistical analysis
Data was analyzed using SAS (Cary, NC; Version 8.2).
Descriptive statistics were used to summarize the patient
cohort.
The Health Research Ethics Board of the University of
Alberta approved this study.
Results
Patients and episodes of FN
From June 1, 1997 to July 1, 2002, the NACCP treated 275
children. Table 1 is a summary of the number of episodes
of FN by diagnosis. All but a small number of children
with neuroblastoma and central nervous system tumors
received chemotherapy. Of the 275 patients, 148 (54%)
were never admitted for FN, and the other 127 patients
had 276 admissions for FN. The highest incidence of
admissions for FN was in patients with osteogenic and
Ewing's sarcoma, with the lowest incidence being in
patients with Wilms tumor and central nervous system
tumors.
Microbiologically documented infections
Cultures taken within 48 hours of admission detected
MDI that could account for the fever in 59 episodes of FN
(21%) in 45 children. Sixteen of these episodes were
attributed to viral infections (9 respiratory syncytial virus,
5 parainfluenza, 1 influenza A and 1 influenza B) and 44
episodes were attributed to bacterial infections (5 urinary
tract infections, 33 episodes of bacteremia, and 5 other
bacterial infections). There were no systemic fungal infec-
tions diagnosed in the 276 admissions for FN. Table 2
shows the incidence of infection according to age group.
Cultures taken more than 48 hours after admission
detected a MDI in eight episodes of FN, but the organisms
isolated may not have been the cause of the original fever.
These infections were documented at a median of 6.5 days
(range 3 – 29 days) after admission to hospital. There
were four viral infections (influenza A, parainfluenza, her-
pes stomatitis (2 episodes)) and four episodes of bactere-
mia (Salmonella enteritidis, viridans streptococci,
coagulase-negative staphylococci (2 episodes)).
Duration of fever
Fever was documented only prior to the hospitalization
and not after admission in 72 of the 217 episodes of FN
without proven bacterial or viral infection at admission.
However, for the 145 episodes where fever was docu-
mented in hospital, the median duration of the initial
fever was 2 days (range 1 – 33 days). There were 39 epi-
sodes of FN in which the fever recurred prior to hospitalBMC Pediatrics 2005, 5:10 http://www.biomedcentral.com/1471-2431/5/10
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discharge and persisted for a median of 3 days (range 2 –
19 days).
Antimicrobial therapy
For two episodes of FN, IVAMT was not initiated, but the
reason for this was not clear. For the remaining 215 epi-
sodes, the most frequently prescribed IV IVAMT was pip-
eracillin/tobramycin (75% of episodes). The median
duration of IVAMT was 5 days (range 1 to 28 days), and
outpatient IVAMT were not used. Oral antibiotic therapy
was used in 17 episodes prior to hospital discharge and in
another six episodes at discharge, but always to treat a spe-
cific infection rather than as empiric therapy for FN.
In 16 episodes of FN, patients were on fluconazole proph-
ylaxis at the time of admission. A systemic antifungal
agent was added during the hospitalization in another 19
episodes (fluconazole in 15, amphotericin B in 3 and
ketoconazole in 1). The anti-fungal was added a median
of 2 days after admission (range 1–10 days).
Clinical course and outcome
The median length of stay in hospital for all FN episodes
was 5 days (range 1 to 33 days). Almost all patients were
discharged on the day their IVAMT was discontinued.
Phagocytic cell counts at the time of discontinuation of
IVAMT are shown in Table 3 (not available in 77 epi-
sodes). The median ANC at the time of discontinuation of
IVAMT was 400/mm3, and in 28/199 episodes (14%),
IVAMT were discontinued before the ANC rose to 100/
mm3. In 13/199 episodes (7%), IVAMT was discontinued
when the absolute phagocyte count (APC) was < 100/
mm3.
Two patients died during their admission for FN. One
patient was receiving palliative care. The other patient
died from complications of graft versus host disease.
None of the patients required readmission because of
clinical deterioration, suspected infection or recurrent
fever prior to their neutropenia resolving.
Table 1: Episodes of febrile neutropenia by diagnosis in 275 pediatric oncology patients.
Diagnosis Number of patients (%) Number of patients with 
FN episodes (%)
Mean number of episodes 
per patient
Range of number of 
episodes per patient
Osteogenic sarcoma 8 (3%) 7 (87%) 3.13 0–7
Ewings sarcoma 5 (2%) 4 (80%) 2.20 0–5
Rhabdomyosarcoma 15 (5%) 11 (79%) 1.93 0–6
Hepatoblastoma 9 (3%) 5 (56%) 1.22 0–5
Acute myeloid leukemia (AML) 16 (6%) 7 (44%) 1.00 0–5
Neuroblastoma 23 (8%) 11 (48%) 0.83 0–5
Non-Hodgkin's lymphoma 24 (9%) 14 (58%) 0.75 0–4
Acute lymphoblastic leukemia (ALL) 85 (31%) 41 (48%) 0.73 0–7
Others * 22 (8%) 9 (41%) 0.41 0–3
Hodgkin's lymphoma 25 (9%) 8 (32%) 0.36 0–5
Central nervous system tumors 26 (9%) 7 (27%) 0.23 0–3
Wilms tumor 17 (6%) 3 (18%) 0.12 0–1
Total 275 127 (46%)
Children with leukemia not in remission were excluded. All but a small number of children with neuroblastoma and central nervous system tumors 
received chemotherapy.
n = number of patients
* adrenocortical carcinoma, epithelial tumor, juvenile myelomonocytic leukemia, Langerhans cell histiocytosis, small cell tumor, teratoma
Table 2: Incidence of proven bacterial or viral infections.
Type of infection Age 0–1 year
n = 40
Age 2–4 years
n = 91
Age ≥  5 years
n = 145
Viral infection 2 (5%) 6 (7%) 7 (5%)
Bacterial infection 9 (23%) 17 (19%) 18 (12%)
Cultures negative 29 (73%) 68 (75%) 120 (83%)
The table shows the number of proven bacterial or viral infections diagnosed on cultures done within 48 hours of admission during 276 admissions 
for FN in pediatric oncology patients.
n = number of episodes of FN in this age rangeBMC Pediatrics 2005, 5:10 http://www.biomedcentral.com/1471-2431/5/10
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With four other episodes of FN, a fever recurred after the
patient was discharged, but prior to their next chemother-
apy treatment. With two of these four episodes, the
patient was not neutropenic at the time of the fever and
cultures were not taken. For the other two episodes, the
patients were neutropenic when the fever recurred (ANC
had been 0 and 200 at discharge), but all cultures were
negative and the children were not readmitted.
Discussion
This study was a review of 276 admissions for FN in 275
pediatric oncology patients over a 5-year period. Almost
half the patients had at least one hospital admission for
FN, with the maximum number of admissions being
seven. Admissions for FN occurred most commonly in
patients with sarcomas, less so in those with leukemia or
lymphoma and least in those with other solid tumors.
However, episodes of FN in children with leukemia who
were not yet in remission were excluded since FN in this
clinical setting often occurs in patients that have other
complicating factors.
Management of FN is a controversial issue. It is clear that
empiric treatment of FN with IVAMT (with addition of
antifungal agents if fever persists) decreases mortality [1].
This is because many of these patients have bacteremia,
and septic shock is a common outcome in neutropenic
patients who are bacteremic with virulent organisms such
as coliforms, Staphylococcus aureus, and even some typi-
cally non-virulent organisms such as viridans streptococci.
However, cultures are never 100% sensitive, not all body
sites are accessible to culture, and it is possible that some
infections in immunocompromised patients are due to
organisms that are cell-wall deficient so are not detected
in routine cultures [2]. A study using high-resolution
computed tomography of the chest in adults with FN
revealed a high incidence of pulmonary infiltrates that
were not evident on plain films [3], so it is possible that at
least some patients with FN have a bacterial pneumonia
that is not diagnosed. Therefore, IV or oral antibiotics are
often continued even if all cultures at presentation are
negative. However, it is now clear that the majority of
adults and children with FN, negative bacterial cultures,
and without clinical evidence of bacterial infection do not
have a partially-treated or occult bacterial infection, and
IVAMT can be discontinued prior to the ANC reaching
500/mm3 [1].
In the current study, an MDI was identified by cultures on
admission in 21% of episodes (16% bacterial, 6% viral),
and based on cultures done more than 48 hours after
admission in 2.8% of episodes (1.4% bacterial, 1.4%
viral). There was no mortality and minimal morbidity
attributable to infection in the other 208 hospital admis-
sions for FN. Almost all episodes were managed with
IVAMT initially, but in 56% of episodes, IVAMT was dis-
continued when the ANC was ≤  500/mm3. Early discon-
tinuation of IVAMT was based on the judgment of the
clinician rather than on standard criteria. Fever recurred in
only 4/112 (4%) of these episodes, and the fever was not
due to bacterial infection and did not result in readmis-
sion in any of these four episodes. This suggests that the
clinicians were able to select patients who could safely
have IVAMT discontinued and be discharged when the
ANC was ≤  500/mm3.
The main potential risk of limiting the duration of IVAMT
is recurrence of a partially treated bacterial infection. Ben-
efits of limiting the duration of antibiotic therapy include
decreasing the duration of hospitalization, decreasing the
risk of antibiotic-related toxicity, and possibly decreasing
the risk of secondary infection with organisms that are
resistant to the antibiotics that were used for empiric treat-
ment of FN. In the current study, there was no evidence of
recurrence of undiagnosed partially treated bacterial infec-
tions after discontinuation of antibiotics. With regard to
secondary bacterial infections, a bacterial infection was
diagnosed based on cultures done more than 48 hours
Table 3: Hematologic parameters when antibiotics were discontinued and at discharge in pediatric oncology patients with FN with 
negative cultures at admission.
Median Range Number (%) < 100 Number (%) 100–500 Number (%) > 500
ANC when antibiotics discontinued (n = 199) 400 0–34900 28 (14%) 84 (42%) 87 (44%)
Monocyte count when antibiotics discontinued (n = 199) 400 0–4400 20 (10%) 117 (59%) 62 (31%)
APC when antibiotics discontinued (n = 199) 800 0–39300 13 (7%) 56 (28%) 129 (65%)
ANC at discharge (n = 194) 500 0–42200
The table shows the hematologic parameters when antibiotics were discontinued and at discharge in pediatric oncology patients with FN with 
negative cultures at admission. There were 217 episodes of FN analyzed in the study, but not all patients had bloodwork done when antibiotics 
were discontinued or at discharge.
n = number of episodes of FN
ANC – absolute neutrophil count
APC – absolute phagocyte count (ANC + monocyte count)BMC Pediatrics 2005, 5:10 http://www.biomedcentral.com/1471-2431/5/10
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after admission in only 4/276 (1.4%) of admissions, and
all four patients were still on IVAMT. In the only pub-
lished pediatric study where 73 patients were randomized
to continue or discontinue antibiotics before the ANC
reached 500/mm3, the rate of documented or probable
secondary bacterial infections was 8% in the group who
continued vs. 6% in the group who discontinued antibi-
otics [4]. Clearly it would require a very large study to
demonstrate if early discontinuation of antibiotics in
selected patients can decrease the risk of secondary bacte-
rial infection.
There were 21 pediatric studies up to 2002 looking at the
outcomes of children with FN who had all antibiotics dis-
continued or were changed to oral antibiotics with ANC ≤
500 /mm3 [5]. In general, outcomes were good if patients
had evidence of marrow recovery at the time of discontin-
uation of IVAMT. However, there is a need for specific cri-
teria in determining when to stop empiric IVAMT in
patients with FN. Risk factors for bacteremia or other seri-
ous bacterial infections that have been validated and
would be identifiable soon after admission include:
1) recent chemotherapy with a platelet count <50,000/
mm3 [6]
2) relapsed leukemia [6]
3) hypotension [6]
4) CRP ≥  90 mg/L [6]
5) absolute monocyte count (AMC) < 100 [7-9]
6) peak temperature ≥  39°C [8,9]
Even these risk factors are not consistent between studies,
which could be because the definitions of significant bac-
terial infections and the populations studied varied [8].
Other factors that have been reported to increase the risk
of bacterial infection such as young age [5], high number
of previous FN episodes [10], marrow involvement [11],
presence of a central venous catheter [11], anticipated
neutropenia > 7 days [5,12], presence of co-morbidities
[12] or recent stem-cell transplant [5] require validation.
Risk factors for bacterial infections after discontinuation
of IVAMT in children with FN are even less well defined.
Most studies to date had insufficient power to look at the
occurrence of bacterial infections after discontinuation of
IVAMT, and used recurrence of fever as an endpoint [5]. As
mentioned previously, there is a correlation between the
absence of marrow recovery and adverse outcome after
discontinuation of IVAMT [1,5], but it is not clear if the
APC, the ANC, the AMC, the platelet count, or some com-
bination of these parameters should be analyzed to deter-
mine that marrow recovery is occurring. In our study,
none of the patients had bacterial infections after IVAMT
was discontinued and only four patients with recurrent
fever, so we were not able to analyze risk factors. Our
study suggests that children selected for early discontinu-
ation of IVAMT by experienced clinicians are likely to have
an excellent outcome. However, further prospective stud-
ies are needed to determine whether using objective crite-
ria (such as an AMC > 100) in addition to clinical
judgment increases the number of children who can safely
have their IVAMT discontinued while they have a low
ANC.
If IVAMT is discontinued with an ANC ≤  500/mm3, there
is no consensus as to whether oral antibiotics should be
substituted until the ANC reaches 500/mm3. All antibiot-
ics were discontinued with an ANC ≤  500/mm3in at least
some patients in 10 of 21 previous pediatric studies, and
oral antibiotics were substituted in the other 11 studies
[5]. The outcomes appear to be comparable with these
two strategies. The only randomized controlled trial of
oral antibiotics versus placebo found no advantages in
using antibiotics [4]. This would suggest that undiagnosed
partially treated bacterial infection is not common in
these patients.
Conclusion
About half of the pediatric oncology patients in our pro-
gram had at least one admission for FN. Intravenous anti-
biotics were discontinued with an ANC ≤  500/mm3 in
about half of episodes of FN, with oral antibiotics then
being prescribed only for patients with proven bacterial
infections. The few secondary bacterial infections
occurred prior to discontinuation of IVAMT, and no
patients required readmission because of suspected or
proven infection. Based on this and previous studies, it is
not necessary to routinely prescribe oral antibiotics in
children who are discharged with an ANC ≤  500/mm3. A
prospective randomized study could determine if use of
objective criteria in addition to clinical judgment could
increase the number of children who can safely have
IVAMT discontinued while still neutropenic.
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